AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
Executive Summary
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards
You may also be interested in...
Hospital Access, Reimbursement Slowing Effient Uptake, Execs Say
It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience
Hospital Access, Reimbursement Slowing Effient Uptake, Execs Say
It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience
FDA Updates Plavix Label, Leaves Effient With Clear Advantage
FDA expands upon the warning that it discreetly slipped into the anti-clotting drug's labeling in May, with new data that clopidogrel is 50% less effective when given with Prilosec.